News
Stay informed with ScinoPharm Taiwan's latest updates on our progress in sustainability and global partnerships.
ScinoPharm Taiwan Announces Approval of Bortezomib Injection for Multiple Myeloma Treatment in Taiwan, Strengthening Domestic Pharmaceutical Supply Chain Resilience
ScinoPharm Taiwan announced that it has successfully obtained marketing approval from the Taiwan Food and Drug Administration (TFDA) for Bortezomib, a treatment for Multiple Myeloma. Following the U.S. FDA approval secured in 2023, the newly granted Taiwan approval marks another significant milestone for the company. This achievement not only highlights ScinoPharm Taiwan’s decades-long expertise in oncology drug development, but also demonstrates its concrete response to the government’s policy to strengthen pharmaceutical supply chain resilience. ScinoPharm Taiwan is currently actively pursuing National Health Insurance reimbursement approval, with the goal of benefiting more patients in Taiwan and firmly anchoring internationally recognized critical manufacturing technologies and high-quality medicines within the local healthcare system.
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the only pharmaceutical company in Taiwan to achieve this historic milestone. This achievement underscores ScinoPharm’s leadership in complex generics and highlights Taiwan’s growing recognition as a trusted contributor to the global pharmaceutical industry.
ScinoPharm Taiwan Hosts Healing Art Forum in Partnership with Formosa Cancer Foundation
ScinoPharm Taiwan recently held its 16th annual ScinoPharm Art Forum, a long-standing public art and cultural lecture series dedicated to enriching lives through art and dialogue.
ScinoPharm Taiwan Continues Strategic Expansion in Formulation and CDMO Businesses
ScinoPharm Taiwan (Stock Code: 1789) held an online investor conference today to report its financial results for the first half of 2025. The company recorded consolidated revenue of US$45.2 million, equivalent to NT$1.434 billion, and a net profit after tax of NT$80 million.
ScinoPharm Taiwan Maintains Stable Operations, Actively Expands into Formulation Development and CDMO Business
ScinoPharm Taiwan (Stock Code: 1789) held an investor conference today to report on its 2024 operational performance and business developments. The company achieved a consolidated annual revenue of NT$3.406 billion, marking a moderate 7% growth. Net profit after tax reached NT$339 million, reflecting an 18% year-over-year increase, with earnings per share (EPS) rising to NT$0.43.
ScinoPharm Partners with Handa Pharmaceuticals to Advance 505(b)(2) Drug Development
ScinoPharm Taiwan, Ltd. today announced a strategic investment in Handa Pharmaceuticals, Inc., marking the beginning of a collaboration to share R&D resources and leverage complementary strengths in advancing 505(b)(2) new drug development. This partnership will drive efforts in research, clinical trials, regulatory approvals, and product commercialization.
ScinoPharm Taiwan Achieves Zero-Deficiency Record in ANVISA Inspection, Expanding Its Presence in Emerging Markets
ScinoPharm Taiwan (SPT) (stock code 1789) has not only solidified its position in the US and EU pharmaceutical markets, but is continuing to extend its reach into promising emerging markets, demonstrating its commitment to expand its global footprint.
ScinoPharm Taiwan H1 performance strong, expands focus on injectable and CDMO businesses
ScinoPharm Taiwan (stock code 1789) reported consolidated revenue of NT$1.646 billion for the first half of 2024, with a post-tax net profit of NT$215 million, representing a 117% increase compared to the same period last year.
ScinoPharm Taiwan Reports 36% YoY Revenue Growth in Q1; Both Injectable Plant and China Subsidiary Pass US FDA Inspection with Zero Deficiencies
ScinoPharm Taiwan (stock code 1789) announced today that its consolidated revenue for the first quarter reached NT$883 million, representing an increase of 36.21% compared to the same period last year. The sales momentum remained robust in the first quarter of 2024, resulting in increased shipments. And The first quarter consolidated net profit reached NT$140 million, marking a remarkable growth of 233% compared to the same period last year.
ScinoPharm Taiwan Exhibits Steady Operation and Bolsters Development of Injectable Products
ScinoPharm Taiwan (stock code 1789) announced consolidated revenue of NT$3.186 billion, net profit after tax of NT$287 million, and earnings per share (EPS) after tax of NT$0.36.
Product & Service
APIs
Drug Products
CDMO Services
VISION
Vision
